Lava Therapeutics N.V. (LVTX) Stock Price, Quote & News

Company Profile

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prosta...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 85 016 3100

Website: www.lavatherapeutics.com

Address:

Yalelaan 62, Utrecht, Netherlands

SweepCastApp Oct. 4 at 10:51 AM

$LVTX: Unusual Options Activity Alerted PUT flow observed 75x contracts at Strike price of $5 Exp on 01/16/2026 with Premium of $31K and showing BEARISH Sentiment

0 · Reply

Thestocktraderhubzee Oct. 3 at 9:58 AM

WATCHLIST OCT 03 2025 $CACI CACI International Wins A Five-Year Contract Valued At More Than $73M To Continue Modernization Of The U.S. Air Force's Integrated Broadcast Service Supporting National Security Efforts Across DOD $CDTX Cidara Secures Up To $339M BARDA Award To Advance CD388 Pandemic Influenza Therapeutic and U.S. Manufacturing $LVTX XOMA Royalty And LAVA Therapeutics Announced The Extension Of The Expiration Of The Tender Offer To Purchase All Outstanding Shares Of Common Shares Of LAVA $GD General Dynamics' Business Unit, General Dynamics Information Technology, Wins $1.25B Enterprise Mission Information Technology Services 2 Task Order To Support U.S. Army Europe and Africa $INTC Intel CEO Lip-Bu Tan Backs $24M Corintis Board As Startup Solves AI's Biggest Bottleneck Problem

0 · Reply

HouseOfTheDragons Oct. 3 at 8:22 AM

Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $CJET $ELPW $NBY $LVTX xxx

0 · Reply

MexaTraders Oct. 2 at 9:15 PM

What's happening on ticker ASTC right now?! Are they pumping ASTC for 300% next? Looks like its breaking out! Shorts overextended - Looks like its about to HALT UP and Squeeze any time! Some will buy it now some will chase it later - dont miss ASTC $ASNS $DFLI $SAVA $LVTX news

0 · Reply

MrTicker Oct. 2 at 8:48 PM

$LVTX XOMA Royalty And LAVA Therapeutics Announced The Extension Of The Expiration Of The Tender Offer To Purchase All Outstanding Shares Of Common Shares Of LAVA BENZINGA 3:47 PM ET 10/2/2025

0 · Reply

MrTicker Oct. 2 at 8:46 PM

$LVTX EMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation(XOMA) and LAVA Therapeutics N.V.(LVTX) (“LAVA”) today announced the extension of the expiration of the tender offer to purchase all outstanding shares of common shares of LAVA, for (i) a cash amount to be determined in accordance with the Purchase Agreement, plus (ii) a non-transferable contingent value right (“CVR”) per share representing the right to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75% of any net proceeds from any out license or sale of LAVA’s unpartnered programs (the “Offer”). The Offer, which was previously scheduled to expire one minute after 11:59 p.m. Eastern Time on October 3, 2025, has been extended until one minute after 11:59 p.m. Eastern time on October 17, 2025, unless the Offer is further extended or earlier terminated. The proposed acquisition is expected to close in the fourth quarter of 2025,

0 · Reply

MrTicker Oct. 2 at 8:45 PM

$LVTX XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. GLOBENEWSWIRE 3:43 PM ET 10/2/2025

0 · Reply

DaBullRunner Oct. 2 at 8:44 PM

$DFLI kept trying to tell you about this one in the .30’s DTCK is going to make a big run soon on that news 🚨 WATCH AND LEARN LIKE HIM👇 $ASNS $MIGI $EPOW $LVTX let’s get it

0 · Reply

StocktwitsNews Sep. 30 at 11:33 AM

LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting $LVTX $XOMA https://stocktwits.com/news/equity/markets/lava-therapeutics-stock-drops-after-company-cancels-shareholder-meeting/chDD4XlR3BN

0 · Reply

biochirp Sep. 29 at 8:03 PM

$LVTX CVR not being correctly valued

0 · Reply

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025

Aug 13, 2025, 4:55 PM EDT - 7 weeks ago

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 5 months ago

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

Apr 16, 2025, 7:30 AM EDT - 6 months ago

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

Mar 28, 2025, 7:30 AM EDT - 6 months ago

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 28, 2025, 12:32 PM EST - 7 months ago

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

Jan 10, 2025, 8:23 AM EST - 9 months ago

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

Dec 10, 2024, 7:30 AM EST - 10 months ago

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Sep 3, 2024, 8:00 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 20, 2024, 7:30 AM EDT - 1 year ago

LAVA Reports Second Quarter 2024 Financial Results and Business Update

Jun 20, 2024, 7:30 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 10, 2024, 7:00 AM EDT - 1 year ago

LAVA Announces Annual Meeting of Shareholders

May 30, 2024, 7:00 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 21, 2024, 7:00 AM EDT - 1 year ago

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

Mar 20, 2024, 7:00 AM EDT - 1 year ago

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

Mar 5, 2024, 7:30 AM EST - 1 year ago

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

Jan 25, 2024, 7:00 AM EST - 1 year ago

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Nov 16, 2023, 7:00 AM EST - 2 years ago

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Sep 6, 2023, 7:11 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 22, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

Jun 14, 2023, 9:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

Jun 8, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Jun 1, 2023, 4:20 PM EDT - 2 years ago

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

Jun 1, 2023, 8:09 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

Apr 11, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Mar 9, 2023, 8:05 AM EST - 2 years ago

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

$LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium$

Feb 16, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

Feb 9, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

Feb 6, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

Jan 23, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

Jan 6, 2023, 1:07 PM EST - 2 years ago

LAVA Therapeutics Announces Appointment of New Directors to the Board

Jan 3, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 10, 2022, 10:00 AM EST - 3 years ago

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 16, 2022, 4:05 PM EST - 3 years ago

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 3, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2022, 9:00 AM EDT - 3 years ago

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 1, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

Oct 18, 2022, 2:32 AM EDT - 3 years ago

LAVA Therapeutics: Assessing A Promising Innovator

Oct 7, 2022, 11:00 AM EDT - 3 years ago

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Sep 13, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Sep 7, 2022, 7:41 AM EDT - 3 years ago

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Jun 16, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Jun 15, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Announces Two Appointments to its Board of Directors

Jun 2, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

Jun 1, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Announces Annual Meeting of Shareholders

SweepCastApp Oct. 4 at 10:51 AM

$LVTX: Unusual Options Activity Alerted PUT flow observed 75x contracts at Strike price of $5 Exp on 01/16/2026 with Premium of $31K and showing BEARISH Sentiment

0 · Reply

Thestocktraderhubzee Oct. 3 at 9:58 AM

0 · Reply

HouseOfTheDragons Oct. 3 at 8:22 AM

0 · Reply

MexaTraders Oct. 2 at 9:15 PM

0 · Reply

MrTicker Oct. 2 at 8:48 PM

$LVTX XOMA Royalty And LAVA Therapeutics Announced The Extension Of The Expiration Of The Tender Offer To Purchase All Outstanding Shares Of Common Shares Of LAVA BENZINGA 3:47 PM ET 10/2/2025

0 · Reply

MrTicker Oct. 2 at 8:46 PM

0 · Reply

MrTicker Oct. 2 at 8:45 PM

$LVTX XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V. GLOBENEWSWIRE 3:43 PM ET 10/2/2025

0 · Reply

DaBullRunner Oct. 2 at 8:44 PM

$DFLI kept trying to tell you about this one in the .30’s DTCK is going to make a big run soon on that news 🚨 WATCH AND LEARN LIKE HIM👇 $ASNS $MIGI $EPOW $LVTX let’s get it

0 · Reply

StocktwitsNews Sep. 30 at 11:33 AM

0 · Reply

biochirp Sep. 29 at 8:03 PM

$LVTX CVR not being correctly valued

0 · Reply

buyandsold Sep. 23 at 12:25 AM

$LVTX https://substack.com/@biospecialsit/note/p-174255085?r=2leqj2

0 · Reply

StockHounding Sep. 21 at 7:18 PM

$ACDC $LIDR $LVTX $NITO $PAVS Good list Your descriptions are always terse and pithy. I like it

1 · Reply

ChartChartist Sep. 21 at 6:03 PM

$ACDC frac and crypto maybe $LVTX im in and out not holding $LIDR getting tight $NITO ill be watching rs $PAVS active on it. Runner setup for this week 🍩

0 · Reply

NVDAMillionaire Sep. 3 at 11:50 AM

$LVTX Excellent article that nails exactly where LVTX stands right now. So if you want to update your LVTX knowledge or get acquainted with LVTX, this is a must read. https://beyondspx.com/quote/LVTX/lava-therapeutics-gammabody-platform-at-a-strategic-crossroads-nasdaq-lvtx#analysis

0 · Reply

Rolo2024 Aug. 31 at 11:53 PM

$LVTX Anyone know approximately what the value of CRV will be? Hopefully more than $.41

2 · Reply

outlawinvestor1 Aug. 20 at 11:22 AM

$LVTX it's arrived. 🤞

0 · Reply

Rolo2024 Aug. 19 at 2:16 PM

$LVTX We are being bought out? Whats the buyout worth?

0 · Reply

bambus3001 Aug. 14 at 11:03 AM

$LVTX Der Deal ,wo landen wir .

0 · Reply

DavidScott Aug. 7 at 2:58 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $BULL $LIXT $CAN $LVTX $NMAX

1 · Reply

JarvisFlow Aug. 5 at 4:24 PM

HC Wainwright & Co. updates rating for LAVA Therapeutics ( $LVTX ) to Neutral, target set at 1.5 → 1.24.

0 · Reply

biochirp Aug. 5 at 3:35 PM

$LVTX CVRs valued at 0.25 it seems 😐 oh well will hold to get them

0 · Reply

JarvisFlow Aug. 5 at 11:00 AM

Jefferies has adjusted their stance on LAVA Therapeutics ( $LVTX ), setting the rating to Hold with a target price of 3 → 1.5.

0 · Reply

Market Cap	40.77M
Revenue (ttm)	11.98M
Net Income (ttm)	-25.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-209.60%
Debt to Equity Ratio	0.00

Volume	91,400
Avg Vol	273,060
Day's Range	N/A - N/A
Shares Out	26.31M
Stochastic %K	79%
Beta	0.50
Analysts	Hold
Price Target	$1.37